Interpretation and Management of Elevated Lipoprotein(a) Levels

Understanding Lp(a) and Its Significance

Lp(a) is an LDL-like particle containing apolipoprotein(a) that accumulates in vascular tissues and aortic valve leaflets, contributing to both atherosclerotic and thrombotic risk, according to the American College of Cardiology 1
Lp(a) contributes to residual cardiovascular risk even when LDL-C is well-controlled, as stated by the American College of Cardiology 1, 2

The American College of Cardiology recommends Lp(a) measurement in patients with premature cardiovascular disease 1, 3
Lp(a) measurement is recommended in patients with familial hypercholesterolemia, according to the American College of Cardiology 1, 3
Patients with a family history of premature CVD or elevated Lp(a) should have Lp(a) measured, as suggested by the American College of Cardiology 1, 3
The American College of Cardiology recommends Lp(a) measurement in patients with recurrent cardiovascular events despite optimal lipid-lowering therapy 1, 3
Lp(a) measurement is recommended in patients with ≥5% 10-year risk of fatal CVD according to risk algorithms, as stated by the American College of Cardiology 1, 3

Traditional thresholds for elevated Lp(a) are >30 mg/dL or >75 nmol/L, approximately the 75th percentile in white populations, according to the American College of Cardiology 1, 4
The European guidelines suggest significant risk when Lp(a) levels are >80th percentile or >50 mg/dL, as stated by the American College of Cardiology 1, 3
The Canadian Cardiovascular Society uses a cutoff of >30 mg/dL to define abnormal Lp(a) levels, according to the American College of Cardiology 1, 3
Risk assessment should consider various Lp(a) cutoffs (>30, >50-60, and >100 mg/dL) to identify patients most likely to benefit from Lp(a) lowering, as suggested by the American College of Cardiology 5, 2

Statins and ezetimibe may increase Lp(a) mass and Lp(a)-C levels, according to the American College of Cardiology 5, 2
Lp(a)-C content is included in standard "LDL-C" laboratory measurements, potentially affecting achievement of LDL-C targets, as stated by the American College of Cardiology 5, 2

Children with elevated Lp(a) levels have a fourfold increased risk of acute ischemic stroke, according to the American College of Cardiology 6
The risk of recurrent ischemic strokes is increased by more than 10-fold in patients with Lp(a) >90th percentile, as stated by the American College of Cardiology 6
Lp(a) levels are substantially increased in persons with end-stage renal disease and chronic kidney disease, according to the American College of Cardiology 7
Lp(a) is an independent predictor of incident coronary heart disease events and mortality in CKD patients, as stated by the American College of Cardiology 7

Failing to measure Lp(a) in high-risk patients, particularly those with premature or recurrent cardiovascular disease, is a common pitfall, according to the American College of Cardiology 1, 3
Relying solely on LDL-C targets in patients with elevated Lp(a) may not adequately address Lp(a)-mediated risk, as stated by the American College of Cardiology 5, 2
Overlooking the contribution of Lp(a)-C to measured LDL-C levels may affect interpretation of lipid profiles, according to the American College of Cardiology 5, 2